Paolo Tarantino, MD

Experts discuss the potential of antibody-drug conjugates in treating triple-negative breast cancer, highlighting ongoing trials and emerging therapies.

Experts discuss the critical unmet needs in triple-negative breast cancer, highlighting innovative treatments and the importance of developing effective biomarkers.

Explore effective strategies for managing side effects of ADC therapy in triple-negative breast cancer, focusing on toxicity and patient care.

Experts discuss the sequencing of antibody-drug conjugates in breast cancer treatment, exploring optimal strategies and emerging clinical data.

Explore the promising role of trastuzumab deruxtecan in treating HER2-low triple-negative breast cancer, highlighting key trial findings and expert insights.

It seems there is no text provided for summarization. Please share the content you'd like summarized, and I'll be happy to help!

Dr. Tarantino discusses the promising results of the Trodelvy breast cancer study, highlighting its impact on treatment for high-risk patients.

Dr. Yuan discusses the ASCENT-03 trial's efficacy, crossover implications, and safety data for sacituzumab govitecan in cancer treatment.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Explore the latest advancements in clinical trials for early-stage triple-negative breast cancer, focusing on promising antibody-drug conjugates (ADCs).

Discover the promising advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative and hormone-positive breast cancer.

Explore the evolving treatment landscape for early-stage triple-negative breast cancer, highlighting innovative therapies and clinical trial insights.

Explore the evolving treatment landscape for early-stage triple-negative breast cancer, highlighting innovative therapies and clinical trial insights.

Explore the latest advancements in antibody-drug conjugates for treating triple-negative breast cancer, addressing critical challenges and innovations.

Experts discuss the transformative impact of antibody-drug conjugates (ADCs) in cancer treatment, emphasizing their growing role and the need for oncologists to adapt.

Experts discuss the need for better biomarker testing in ADC trials to ensure more patients benefit from targeted therapies.

Experts discuss the potential of maintenance strategies for antibody-drug conjugates in breast cancer, aiming to enhance patient outcomes and manage toxicity.

Explore the innovative world of antibody-drug conjugates, revolutionizing cancer treatment with targeted therapies and reduced side effects.

Explore the evolving landscape of antibody-drug conjugates (ADCs) for breast cancer treatment and the strategic sequencing of therapies.

Explore the latest findings on Phase 3 trials for metastatic triple-negative breast cancer, highlighting treatment efficacy and toxicity profiles.

A new drug shows promise in treating triple-negative breast cancer, significantly improving survival rates and offering hope for better treatment options.

Discover how novel antibody-drug conjugates effectively target brain metastases, offering hope for reducing CNS recurrences in cancer patients.

Experts analyze groundbreaking antibody drug conjugate findings from ESMO 2025, highlighting their impact on breast cancer treatment strategies and patient care.

Paolo Tarantino, MD, PhD, discussed the clinical implications of the DESTINY-Breast11 trial of T-DXd/THP in high-risk, HER2-positive early breast cancer.

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Paolo Tarantino, MD, PhD, discusses the clinical utility of data from the phase 3 neoCARHP trial in patients with HER2-positive early breast cancer.

Paolo Tarantino, MD, PhD, discusses key efficacy data with de-escalated THP with/without carboplatin in HER2-positive breast cancer.

Paolo Tarantino, MD, PhD, discusses the role of genomic testing for guiding treatment decisions for patients with HER2-positive breast cancer.

Paolo Tarantino, MD, PhD, discusses the design and background of the CompassHER2 pCR trial of THP in HER2-positive breast cancer.